Orthobond Launches OSTAGUARD™ Coated Implants
Orthobond Corporation, an innovative leader in antibacterial surface technologies, proudly announces the successful delivery of its OSTAGUARD™ coated implants for surgeries. This breakthrough achievement comes shortly after the FDA granted De Novo clearance for OSTAGUARD. This remarkable coating is specifically designed to combat bacteria that can contaminate medical devices in operating rooms, showcasing a significant advancement in patient safety.
Milestone Achievement in Record Time
David Nichols, the Chief Executive Officer of Orthobond, expressed immense pride in reaching this milestone within such a short timeframe. "We have established ten effective partnerships across various medical applications. This includes areas like orthopedics, ophthalmology, dental, ENT, and plastic surgery reconstruction," Nichols stated. These partnerships highlight the widespread industry interest in leveraging innovative antibacterial technologies to address critical clinical challenges.
Innovative Technology for Infection Control
OSTAGUARD stands out in the market as it is the first coating to receive this De Novo classification, underscoring its significance in controlling bacteria on medical devices. The patented technology has undergone extensive testing against a wide range of microbes, representing almost all types of device-related infections. As part of the manufacturing process, OSTAGUARD is applied to the device surface prior to packaging and sterilization, offering clear advantages to clinicians relying on these medical innovations.
Revolutionizing the Medical Device Industry
George Landau, Executive Vice President of Business Development and Commercialization at Orthobond, remarked on the implications of the OSTAGUARD technology: "With the implementation of OSTAGUARD and its US commercialization, we aim to revolutionize the medical device industry by setting new standards for infection control and patient safety." As Orthobond continues to grow and form new partnerships, the focus remains on delivering progressive solutions tailored to the changing needs of the medical community.
About Orthobond Corporation
Orthobond Corporation specializes in developing advanced surface technologies with a focus on antibacterial properties across various sectors, including medical devices, automotive, and industrial applications. One of their recent achievements includes obtaining FDA De Novo clearance for their groundbreaking OSTAGUARD coating, initially applied in orthopedic spinal implants. This milestone emphasizes Orthobond's commitment to addressing critical issues in infection control and improving patient outcomes.
Frequently Asked Questions
What is OSTAGUARD™?
OSTAGUARD™ is a non-eluting coating developed by Orthobond to actively kill bacteria contaminating medical device surfaces during surgical procedures.
What industries can benefit from Orthobond's technology?
The technology has applications in various fields, including orthopedics, ophthalmology, ENT, plastic surgery reconstruction, and dental.
How quickly are Orthobond's implants being delivered?
Orthobond has achieved timely delivery of its OSTAGUARD™ coated implants, shortly after receiving FDA De Novo clearance.
What does De Novo clearance mean?
De Novo clearance signifies that a new medical device has been approved for use after demonstrating safety and effectiveness to the FDA standards.
How does OSTAGUARD™ improve patient safety?
By actively killing bacteria on medical device surfaces, OSTAGUARD™ significantly reduces the risk of device-related infections, thereby enhancing patient safety.
